Join Adverum’s President and CEO Laurent Fischer, M.D., for a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, where he’ll share our latest company highlights. Learn more here: https://bit.ly/3SyyaMA #genetherapy #wetAMD
Adverum Biotechnologies
Biotechnology Research
Redwood City, California 10,969 followers
We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss.
About us
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
- Website
-
http://www.adverum.com
External link for Adverum Biotechnologies
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Redwood City, California
- Type
- Public Company
- Founded
- 2012
- Specialties
- Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina
Locations
-
Primary
Get directions
100 Cardinal Way
Redwood City, California 94063, US
Employees at Adverum Biotechnologies
Updates
-
We are thrilled to announce the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Ixo-vec, our investigational IVT #genetherapy for #wetAMD. Just like Breakthrough Therapy designation, RMAT for genetic medicines provides the benefits of intensive FDA guidance and potential expedited review processes as we continue to develop our lead candidate. Learn more here: https://bit.ly/46zm5MH
-
-
People with #wetAMD navigate lifelong, burdensome eye injections. Sadly, this high treatment burden results in undertreatment, which in turn leads to preventable vision loss. Earlier this week, we presented positive clinical data from our landmark LUNA Phase 2 trial at #ASRS2024 – demonstrating the potential of a single-injection #genetherapy that could improve quality of life for #wetAMD patients and their families tremendously. Learn more: https://bit.ly/3Y5bs1W
-
-
We presented our landmark 26-week data from our LUNA Phase 2 clinical trial for our single-injection #genetherapy in patients with #wetAMD at #ASRS2024, including a pre-specified patient preference survey at 26 weeks reinforcing the challenges patients experience with current treatment options and the promise for gene therapy with Ixo-vec. Learn more: https://bit.ly/3Y5bs1W
-
-
Adverum Biotechnologies reposted this
Today we announced landmark 26-week data from our LUNA Phase 2 clinical trial for our single-injection gene therapy in patients with #wetAMD at #ASRS2024 that demonstrate a potential best-in-class product profile in a broad population, including hard-to-treat patients requiring 10 mean annualized IVT anti-VEGF injections a year. We’ve also shared the dose level we’d like to move forward with for our Phase 3 program. Learn more: https://bit.ly/3Y5bs1W #ASRS2024 #wetAMD #genetherapy
-
Today we announced landmark 26-week data from our LUNA Phase 2 clinical trial for our single-injection gene therapy in patients with #wetAMD at #ASRS2024 that demonstrate a potential best-in-class product profile in a broad population, including hard-to-treat patients requiring 10 mean annualized IVT anti-VEGF injections a year. We’ve also shared the dose level we’d like to move forward with for our Phase 3 program. Learn more: https://bit.ly/3Y5bs1W #ASRS2024 #wetAMD #genetherapy
-
#ASRS2024 we hope to see you tomorrow at the presentation of our 26-week landmark clinical data from our Phase 2 clinical trial during the Wet AMD Symposium I at the ASRS – American Society of Retina Specialists Annual Scientific Meeting. Join us at the presentation or our Webcast to learn about the potential for our one-time IVT #genetherapy to address the needs and treatment burden of #wetAMD patients, their families and even retina specialists alike. Learn more: https://bit.ly/3S0LGIv
-
-
This week, we’re presenting landmark 26-week data from our LUNA Phase 2 trial at #ASRS2024 – demonstrating the potential of our single-injection #genetherapy to improve lifelong vision and address the burden of current treatment options. Learn more about us https://bit.ly/3S0LGIv
-
-
Join our webcast at 8am EDT July 17 to learn more about our landmark 26-week interim analysis of LUNA, our Phase 2 clinical trial evaluating Ixo-vec. Ixo-vec is a single intravitreal injection #genetherapy for patients with #wetAMD. The clinical data will be presented at #ASRS2024: https://bit.ly/3S0LGIv We hope you can join us!
-
-
As Pride Month comes to a close, we at Adverum are proud to celebrate the vibrant contributions of our LGBTQ+ colleagues, partners, and the broader community. In the dynamic and innovative world of biotechnology, diversity fuels discovery, and inclusion drives progress. This June, we hosted events to support and uplift LGBTQ+ voices. Thank you to everyone who participated. Let's continue striving for a future where everyone can thrive and be their authentic selves. Happy Pride! 🏳️🌈✨ #PrideMonth #DiversityAndInclusion #LoveIsLove #LGBTQ #Pride2024 #BiotechInnovation
-